ELF SANOFI SAYS WILL TAKE CHARGE IN 1993

29 November 1993

French health and beauty group Elf Sanofi has issued a statement saying that it will be taking a charge after tax amounting to 350 million French francs ($59.1 million) in the 1993 financial year that will bring estimated net income for 1993 to 800 million francs.

Consolidated earnings for 1993, barring "any materially adverse unforeseen external factors," are expected to exceed those achieved in 1992.

There has been some speculation recently that Elf Acquitaine, which holds a 51% stake in Elf Sanofi, may divest some of its non-care businesses, such as the beauty products business, Yves Saint Laurent. These rumors were fired last week by comments made to the press by Philippe Jaffre, chairman of Elf Acquitaine, suggesting that he would make a "clean sweep" of financial participations that had nothing to do with the oil business.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight